ClinicalTrials.gg
CompletedNCT05803798TEBELIDUpdated Jan 5, 2026

Combined Treatment With Pulsed Light and Photobiomodulation Before Laser Refractive Surgery

An interventional study of IPL+LLLT in Dry Eye and Dry Eye After LASIK-Laser in Situ Keratomileusis, sponsored by University Hospital, Brest. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Dry Eye Syndromes with a site in France — 13 open to participants now, 14 under way, none of them phase 3. Dry Eye Syndromes · France.

Enrollment
28th of 40
62 · median 81
Started
2023
with 3 others
No phase
28 of 47
9 open now
Registered
32nd of 47
by date

Among the 47 studies in Dry Eye Syndromes with a site in France, this one is the 28th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2023, is one of 28 with no phase, and was the 32nd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

13 of the 47 studies in Dry Eye Syndromes with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Dry Eye Syndromes with a site in France, or all of them as a file.
02

Study summary

Laser corneal refractive surgery is a widely adopted approach for correcting refractive errors, but postoperative dry eye remains a common side effect. Intense Pulsed Light (IPL) and Low-Level Light Therapy (LLLT) are two emerging treatments that have shown potential in managing dry eye disease. However, their role as a prophylactic treatment in patients without pre-existing symptomatic dry eye undergoing refractive surgery has not been explored.

Read the detailed description

monocentric, randomized, simple bling, controlled study

03

Conditions studied

  • Dry Eye
  • Dry Eye After LASIK-Laser in Situ Keratomileusis

Browse trials for

Keywords

  • dry eye
  • laser refractive surgery
  • smile
  • lasik
  • presbylasik
  • photorefractive keratectomy
  • intense-pulsed light
  • low-level-light therapy
  • photobiomodulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Patients eligible for laser corneal refractive surgery (FS-LASIK, SMILE®, or PRK) who meet the inclusion criteria will be enrolled.

Exclusion criteria include age \< 18 and to IPL or LLLT (e.g., pregnancy, lactation, migraine, epilepsy, palpebral or periocular lesion, photosensitive drugs, cardiac pacing system or implantable cardiovertor defibrillator, Fitzpatrick phototypes V and VI).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    treatment

    preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group

    Device: IPL+LLLT

  • No intervention
    standard

    non preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group = standard care

Interventions

  • DeviceIPL+LLLT

    preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery

06

What researchers measure

Primary outcomes

  1. French version of Ocular Surface Disease Index (OSDI) score

    The OSDI questionnaire measures frequency of symptoms, environmental triggers and vision related quality of life. OSDI values range from 0 to 100. A score between 13 and 22 excluded indicates a medium intensity eye dryness. A score between 22 and 33 indicated a moderate intensity eye dryness. A score above 33 indicates a severe eye dryness.

    Time frame: 1 month post-operative

Secondary outcomes

  1. Evolution of Fluorescein Break-up Time (FBUT) over the 6 first months post-operative

    Sodium fluorescein eye drops is instilled in the eye to enhance visibility of the tear film measure tear film breakup time is. Selected cut-off value is 10 seconds. A score below 10 seconds favors dry eye.

    Time frame: 6 months post-operative

  2. Evolution of Schirmer I test over the 6 first months post-operative

    The Schirmer I test, used without anesthesia, provides an estimation of stimulated reflex. Cut-off value used is \<= 10 mm / 5 minutes.

    Time frame: 6 months post-operative

  3. Evolution of Meibomian Gland Dropout over the 6 first months post-operative

    Meibomian Gland Dropout: Evaluated via infrared images using LipiView™ II (Quantel Medical) and graded using the Gestalt Grading Scale (GGS), which scores meibomian gland loss on a scale from 1 (no loss) to 4 (\>75% loss).

    Time frame: 6 months post-operative

  4. Evolution of the Oxford score over the 6 first months post-operative

    The Oxford score is composed of 0 to V grades, dependent on intensity of punctate staining displayed. pictorially across a combination of the cornea and conjunctiva.

    Time frame: 6 months post-operative

  5. Evolution of visual acuity over the 6 first months post-operative

    Visual acuity measured preoperatively (corrected) and postoperatively (uncorrected) using the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale at 4 meters. Visual acuity is scored by adding 30 to the total number of letters read correctly at 4 meters

    Time frame: 6 months post-operative

  6. Evolution of the French version of Ocular Surface Disease Index (OSDI) score over the 6 first months post-operative

    The OSDI questionnaire measures frequency of symptoms, environmental triggers and vision related quality of life. OSDI values range from 0 to 100. A score between 13 and 22 excluded indicates a medium intensity eye dryness. A score between 22 and 33 indicated a moderate intensity eye dryness. A score above 33 indicates a severe eye dryness.

    Time frame: 6 months post-operative

07

Study locations

1 site
  • CHU Brest
    Brest, France
08

References and documents

Publications

  • Dartt DA. Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res. 2009 May;28(3):155-77. doi: 10.1016/j.preteyeres.2009.04.003. Epub 2009 Apr 17. PubMed 19376264 ↗
  • Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II pathophysiology report. Ocul Surf. 2017 Jul;15(3):438-510. doi: 10.1016/j.jtos.2017.05.011. Epub 2017 Jul 20. PubMed 28736340 ↗
  • Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC, Jones L, Craig JP. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017 Jul;15(3):539-574. doi: 10.1016/j.jtos.2017.05.001. Epub 2017 Jul 20. PubMed 28736342 ↗
  • Tashbayev B, Yazdani M, Arita R, Fineide F, Utheim TP. Intense pulsed light treatment in meibomian gland dysfunction: A concise review. Ocul Surf. 2020 Oct;18(4):583-594. doi: 10.1016/j.jtos.2020.06.002. Epub 2020 Jul 3. PubMed 32629039 ↗
  • Cote S, Zhang AC, Ahmadzai V, Maleken A, Li C, Oppedisano J, Nair K, Busija L, Downie LE. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559. PubMed 32182637 ↗
  • McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. Ocul Surf. 2016 Apr;14(2):144-67. doi: 10.1016/j.jtos.2015.11.002. Epub 2015 Dec 28. PubMed 26733111 ↗
  • Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, Viso E, Vitale S, Jones L. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017 Jul;15(3):334-365. doi: 10.1016/j.jtos.2017.05.003. Epub 2017 Jul 20. PubMed 28736337 ↗
  • Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, Kim T, Mehta JS, Messmer EM, Pepose JS, Sangwan VS, Weiner AL, Wilson SE, Wolffsohn JS. TFOS DEWS II iatrogenic report. Ocul Surf. 2017 Jul;15(3):511-538. doi: 10.1016/j.jtos.2017.05.004. Epub 2017 Jul 20. PubMed 28736341 ↗
  • Denoyer A, Landman E, Trinh L, Faure JF, Auclin F, Baudouin C. Dry eye disease after refractive surgery: comparative outcomes of small incision lenticule extraction versus LASIK. Ophthalmology. 2015 Apr;122(4):669-76. doi: 10.1016/j.ophtha.2014.10.004. Epub 2014 Nov 22. PubMed 25458707 ↗
  • Kim TI, Alio Del Barrio JL, Wilkins M, Cochener B, Ang M. Refractive surgery. Lancet. 2019 May 18;393(10185):2085-2098. doi: 10.1016/S0140-6736(18)33209-4. PubMed 31106754 ↗
  • Kerkouri S, Garcin T, Cochener B. Study protocol for a randomised controlled trial to evaluate the prophylactic efficacy of combined intense pulsed light (IPL) and low-level light therapy (LLLT) in preventing laser corneal refractive surgery-induced dry eye: the Treat Eye Before Laser induced Dry (TEBeLiD) study. BMJ Open. 2026 Feb 26;16(2):e095089. doi: 10.1136/bmjopen-2024-095089. PubMed 41748188 ↗

Individual participant data

Plan to share: Yes — De-identified (coded/pseudonymised) individual participant data from the TEBeLiD randomized trial that underlie the primary and secondary publications/final study report. Dataset includes baseline demographics/clinical characteristics, randomization group, procedural variables, follow-up outcomes (e.g., F-OSDI/OSDI, tear film break-up time, corneal staining/Oxford score, Schirmer test, meibomian gland assessment/meibography), adverse events, and protocol deviations. A data dictionary and variable coding will be provided.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available beginning five years and ending fifteen years following the final study report completion

Access criteria: Data access requests will be reviewed by the internal committee of Brest University Hospital (CHU de Brest). Requests must include a research proposal and analysis plan (and ethics approval/exemption if applicable). Approved requestors will be required to sign and comply with a data access/data use agreement (no re-identification; secure storage; no onward sharing; acknowledgement/citation of TEBeLiD investigators). Data will be provided via secure transfer or controlled-access environment.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Nov 2024, 17 months.

Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 17 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 7, 2023
StartActual
Jun 6, 2023
Primary completionActual
Nov 27, 2024
CompletionActual
Apr 16, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05803798
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Jun 6, 2023
Primary completion
Nov 27, 2024
Completion
Apr 16, 2025
Last update
Jan 5, 2026

Study contacts

Béatrice COCHENER-LAMARD, MD, PhD
principal investigator · Universitary Hospital of Brest

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion